Subscribe To

Price Alert Latest News Economic Calendar News

BIIB / Biogen stock edges lower after Medicare restrictions on Aduhelm finalized

Shares of Biogen Inc. BIIB, +0.92% fell 0.3% in the extended session Thursday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said they had finalized their policies about covering the biotech's controversial Alzheimer's drug Aduhelm and future others. As it signaled in January, CMS said that Food and Drug Administration-approved monoclonal antibodies such as Aduhelm and others in its class would be covered for people with Medicare only if they are enrolled in clinical trials. Read More

Demo Live Account See Partner Details

Content Topics

Biogen

Stock

Edges

Lower

After

Medicare

Restrictions

Aduhelm

Finalized

BIIB

Posted: Apr 7 2022, 17:21

Author Name: Market Watch

BIIB News

By Zacks Investment Research
October 30, 2023

Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know

The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.

By Barrons
October 26, 2023

Biogen and Eisai's Revised Alzheimer's Drug Works, but Safety Questions Linger

Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer's drug.

By Market Watch
October 25, 2023

Biogen and Eisai release new Alzheimer's drug data that may support wider uptake

Biogen Inc. and Eisai Co. late Wednesday released new data on their Alzheimer's treatment Leqembi that may ultimately help bolster uptake of the drug.

By Zacks Investment Research
October 23, 2023

Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market

The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.

By Reuters
October 23, 2023

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rh

By GlobeNewsWire
October 19, 2023

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc

By Zacks Investment Research
October 17, 2023

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.

By CNBC Television
October 11, 2023

Final Trades: WST, BIIB, SPY & MDT

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.